Principal Investigator
Li Jianyong, Doctor
The First Affiliated Hospital with Nanjing Medical University
Total Trials
1
As PI
1
Completed
0
h-index
N/A
Publications
0
Years Active
0
Research Impact
h-index
N/A
Research impact score
Publications
0
Total publications
Trial Results
0
Published trial results
Citations
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Phase 11
Trial Status
Terminated1
Role Distribution
Principal Investigator1
PI Rate100%
Activity Timeline
Clinical Trials (1)
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
Relapsed or Refractory B-cell Hematologic Malignancies
PrincipalinvestigatorStart date: 2021-04-01
Research Network
Collaboration Network
2 collaborators·1 connections
Network Legend
KOL
Current InvestigatorCO
High-influence CollaboratorCO
CollaboratorClick: view details
Double-click: go to profile
Drag: move node
Research Areas & Affiliations
Therapeutic Areas
Affiliations
The First Affiliated Hospital with Nanjing Medical University
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
2 similar investigators found
Lei Fan
The First Affiliated Hospital with Nanjing Medical University
3 trials
Shared therapeutic areas:
Relapsed or Refractory B-cell Hematologic Malignancies
Similarity Score30%
Song Yuqing, Doctor
Peking University Cancer Hospital & Institute
1 trials
Shared therapeutic areas:
Relapsed or Refractory B-cell Hematologic Malignancies
Worked with same sponsors:
Sunshine Lake Pharma Co., Ltd.
Collaborated on 1 trial
Similarity Score14%
Publications (0)
No publications found for this investigator.
Clinical Trials (1)
Showing 1 of 1 trials
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
Relapsed or Refractory B-cell Hematologic Malignancies
All 1 trials loaded